What are you looking for?
All Filters
Therapeutic Area
Therapeutic Area
Date Published
Date published
Group 2458.png

SCEMBLIX (asciminib) has simple, once or twice-daily oral dosing1

 

SCEMBLIX is indicated for the treatment of patients 18 years of age and above with:1
 

  • Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in chronic phase (CP) previously treated with two or more tyrosine kinase inhibitors.
  • Ph+ CML in CP with the T315I mutation.
  • Simple Oral Dosing
  • Dose Modification Schedule
  • Drug Interactions

    Recommended dosage in Ph+ CML-CP, previously treated with ≥2 TKIs1

    image 56.png

    Ph+ CML CP harbouring the T315I mutation The recommended dose of SCEMBLIX is 200 mg taken orally twice daily at approximately 12 hour intervals.1

    image 59.png
    image 60.png
image 57.png
image 58.png

AE, adverse event; CML, chronic myeloid leukaemia; MOA, mechanism of action; MMR, major molecular remission; Ph+ CML-CP, Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase; STAMP, Specifically Targeting the ABL1 Myristoyl Pocket; TKI, tyrosine kinase inhibitor; URTI, upper respiratory tract infection. CCyR, complete cytogenetic remission; CML-CP, chronic myeloid leukaemia in chronic phase; IS, international scale; MCyR, major cytogenetic response; MMR, major molecular response; STAMP, specifically targeting the ABL1 myristoyl pocket; TKI, tyrosine kinase; BID, twice daily; QD, once daily; CYP, cytochrome P450; BCRP, breast cancer resistance protein; UGT, UDP glucuronosyltransferase.

 

SCEMBLIX is indicated for the treatment of patients 18 years of age and above with:1

 

  • Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).
  • Previously treated Ph+ CML in CP.
  • Ph+ CML in CP with the T315I mutation

SCEMBLIX™  20mg and 40mg NSS

PDF
View

References

  1. SCEMBLIX (asciminib) approved Product Information.